Innovation
into.blood
Developing
therapies.for
the.treatment
of.rare.diseases
Developing and commercializing specialized therapies for the treatment of rare diseases by using the patient’s own blood
Latest News
View allTaking part in the First International Campaign Raising Awareness for Ataxia ...
December 04, 2020
Read moreEryDel Appoints Dr Esin Kosal, PhD,as Senior Vice President, Global Regulatory ...
November 30, 2020
Read more
Our Technology
EryDel’s proprietary platform technology is an easy to use, fast and automatic bedside procedure, to encapsulate small and large molecules including therapeutic enzymes in patients’ red blood cells. The cells are immediately re-infused into patients providing prolonged half-life in circulation, reduced immunogenicity, better tolerability and predictable vascular distribution.
DiscoverA late Stage
and Broad Pipeline

